---

---

tags : Phase 1    symbols : SRNE   

save search

---

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.3% | O: -2.11% H: 0.0% C: -10.79%
sp-104 fibromyalgia trial phase 1

---

Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern
Published: 2022-04-25 (Crawled : 14:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.42% | O: 0.0% H: 5.26% C: 2.92%
sti-9167 fda antibody sars-cov-2 authorization phase 1

---

Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIELD), a Potent Neutralization Antibody Against Covid-19 Viruses
Published: 2022-03-02 (Crawled : 18:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.59% | O: 1.02% H: 0.0% C: 0.0%
sti-9199 covid-19 fda covid phase 1 authorization antibody

---

Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
Published: 2021-08-23 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.89% | O: -1.46% H: 3.98% C: 3.41%
rheumatoid arthritis phase 1 positive results drug drug delivery liver phase 1b phase 2b

---

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.88% | O: 1.71% H: 1.8% C: -0.12%
fda phase 1 therapy trial authorized t-cell

---

Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
Published: 2021-06-11 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.89% | O: 0.92% H: 2.5% C: 0.68%
fda clearance fda phase 1 drug research technology drug delivery liver phase 1b clearance phase 2b

---

Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
Published: 2021-04-20 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.87% | O: 0.8% H: 1.85% C: -1.72%
covid treatment positive results phase 1 positive results phase 1b phase 2b

---

Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Published: 2021-03-25 (Crawled : 21:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.88% | O: -3.55% H: 7.49% C: 5.9%
covid treatment positive results phase 1 positive results phase 1b phase 2b

---

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.89% | O: 1.37% H: 2.41% C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance

---

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
Published: 2020-12-09 (Crawled : 14:05) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K |

Health Technology

| -99.87% | O: 10.51% H: 2.29% C: -5.96%
covid fda clearance fda trial phase 3 phase 1 phase 2 clearance

---

Gainers vs Losers

74%

26%

Top 10 Gainers

MTTR | News M | $4.8 175.86% 63.6% 71M |

AGBA | $2.5 100.0% 56.6% 200M |

Finance

MLEC | $2.47 76.43% 42.62% 78M |

n/a

NUWE | $0.334 29.96% 40.99% 2.5M |

Manufacturing

EDBL | News | $6.26 66.49% 40.13% 16M |

ATGL | $2.86 46.25% 32.8% 180K |

VIVK | $1.43 33.65% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.7M |

SDIG A | $3.64 35.32% 26.0% 990K |

PROK | $2.72 33.33% 24.58% 2.6M |

---

Your saved searches

---